Toxicities and related improvements of CAR-T Cell in the treatment of cancer

Abstract

Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary new therapy. Since its first discovery, CAR-T therapy has become the fastest growing and most widely used branch of anti-cancer immunotherapy. The field of hematological malignancies has undergone a rapid transformation due to the advent of this technology, which is responsible for over 50% of all cell therapies that are being developed or sold nowadays. With the extensive use of CAR-T cell technologies, more and more advantages and uses have emerged. However, as CAR-T was approved for marketing, shortcomings and toxicities such as CRS, CRES, and cytopenias were also discovered in clinical practice. A number of limitations, including high prices, limited accessibility, and unregulated quality also restrict CAR-T cell therapy’s further promotion and application. This review focuses on CAR-T cell therapy’s mechanisms, toxicities, related improvements, and future developments. Also, this article makes an analysis and summary of CAR-T therapy, hoping to provide a feasible reference for future research.